In an era of intense regulatory scrutiny, digital traceability, and constant operational pressure, pharmaceutical failures no longer arise from missing rules or weak oversight, but from everyday decisions that appear reasonable, compliant, and defensible at the time they are made. Recalls, warning letters, data integrity crises, and consent decrees are rarely sudden events; they are the visible outcome of long periods of unnoticed judgment drift shaped by uncertainty, incentives, authority structures, and success narratives. This book exists because the industry repeatedly asks what went wrong, instead of examining why flawed decisions felt right when they were taken. Regulatory frameworks define targets but cannot prescribe how ambiguity should be interpreted, when escalation should override momentum, or how pressure reshapes reasoning, and it is within this unspoken space that modern failure is formed. Rather than serving as a GMP manual or audit checklist, this book examines how judgment actually operates inside compliant systems, showing how documentation reassures while concealing risk, CAPAs close without correcting trajectories, metrics reward comfort over insight, and routine choices convert uncertainty into long-term exposure. It explains why organizations that pass inspections and employ experienced professionals still fail, not due to lack of effort or intent, but due to invisible decision drift embedded in their systems. By treating judgment as a system property shaped by incentives, authority, and escalation costs, and by reframing failure as evidence rather than embarrassment, this book provides QA leaders, regulatory professionals, site heads, auditors, and executives with a disciplined way to recognize risk early, defend decisions under scrutiny, and redesign governance before collapse occurs, demonstrating that until judgment itself is examined and engineered, compliance alone will never be enough.